UTILISATION D'ACAMPROSATE POUR MODULER L'ACTIVATION D'ERK 1/2 DANS DES MODELES ANIMAUX POUR SXF ET TSA ET INDIVIDUS CHEZ LESQUELS ON A DIAGNOSTIQUE LE SXF ET LE TSA
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
发明人:
ERICKSON, CRAIG,LAHIRI, DEBOMOY
申请号：
CA2926645
公开号：
CA2926645A1
申请日:
2014.10.14
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERKl/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERKl/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERKl/2 activation levels can be used to monitory patients treated with acamprosate.
